The above results indicate that cPKM promotes ICC tumor proliferation, migration, and paclitaxel resistance by upregulating STMN1 expression and activating the AKT pathway through interactions with IGF2BP2 and miR‐199a‐5p. The gene discussed is STMN1; the disease is intrahepatic cholangiocarcinoma.